Dasabuvir

Hepatitis C Virus Non-Nucleoside NS5B Palm Polymerase Inhibitor — ANTIINFECTIVES FOR SYSTEMIC USE

Key facts

Dasabuvir is an ofm drug in the Hepatitis C Virus Non-Nucleoside NS5B Palm Polymerase Inhibitor class catalogued in DrugCentral. It was first approved by the EMA in 2014. Its mechanism of action is classified as Breast Cancer Resistance Protein Inhibitors, RNA Replicase Inhibitors and UGT1A1 Inhibitors. DrugCentral lists 2 molecular targets, including NS5B and CRBN. Recorded indications include Chronic hepatitis C.

• Approval status: ofm (first approved 2014 by the EMA).
• Drug class: Hepatitis C Virus Non-Nucleoside NS5B Palm Polymerase Inhibitor.
• Mechanism of action: Breast Cancer Resistance Protein Inhibitors; RNA Replicase Inhibitors; UGT1A1 Inhibitors.
• Molecular targets: NS5B and CRBN (2 listed in DrugCentral).
• Indications: Chronic hepatitis C.
• ATC code: J05AP09 (Antivirals for treatment of HCV infections).
• Molecular formula: C26H27N3O5S; molecular weight 493.58 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

• Chronic hepatitis C

Mechanism & targets

• Mechanism of action (MoA): Breast Cancer Resistance Protein Inhibitors; RNA Replicase Inhibitors; UGT1A1 Inhibitors
• Established pharmacologic class: Hepatitis C Virus Non-Nucleoside NS5B Palm Polymerase Inhibitor

Molecular targets (2)

Target	Gene	Action	Activity
NS5B protein	NS5B	unknown	EC50 8.74
Protein cereblon	CRBN	unknown	Ki 5.33

Regulatory approvals (2)

Date	Agency	Marketed as	Applicant	Orphan
2014-12-19	FDA	—	ABBVIE INC
2014-11-20	EMA	—	AbbVie Ltd

ATC classification

ATC code	Therapeutic hierarchy
J05AP09	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Antivirals for treatment of HCV infections
J05AP52	ANTIINFECTIVES FOR SYSTEMIC USE › ANTIVIRALS FOR SYSTEMIC USE › DIRECT ACTING ANTIVIRALS › Antivirals for treatment of HCV infections

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

• Swissmedic label: IFNL3 · Actionable PGx

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA term	LLR
Hyperbilirubinaemia	630.2
Jaundice	608.0
Hepatocellular carcinoma	578.3
Hepatic failure	508.2
Ascites	472.3
Blood bilirubin increased	377.0
Renal impairment	312.1
Hepatic encephalopathy	294.7
Drug interaction	207.6
Anaemia	202.4
Hepatic cirrhosis	175.9
Asthenia	137.9

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Dasabuvir is on its molecule page.

• Molecular formula: C₂₆H₂₇N₃O₅S
• Molecular weight: 493.58 g/mol
• CAS number: 1132935-63-7
• InChIKey: NBRBXGKOEOGLOI-UHFFFAOYSA-N
• PubChem CID: 56640146

COC1=C(C=C(C=C1C(C)(C)C)N1C=CC(=O)NC1=O)C1=CC=C2C=C(NS(C)(=O)=O)C=CC2=C1

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Dasabuvir used for?

DrugCentral lists the following indications for Dasabuvir: Chronic hepatitis C.

How does Dasabuvir work?

Dasabuvir is classified as Breast Cancer Resistance Protein Inhibitors, RNA Replicase Inhibitors and UGT1A1 Inhibitors; its molecular targets in DrugCentral include NS5B and CRBN.

When was Dasabuvir first approved?

Dasabuvir was first approved by the EMA in 2014.

What drug class does Dasabuvir belong to?

Dasabuvir is in the Hepatitis C Virus Non-Nucleoside NS5B Palm Polymerase Inhibitor class.

What is the chemical formula of Dasabuvir?

Dasabuvir has the molecular formula C26H27N3O5S and a molecular weight of 493.58 g/mol.

Sources

• DrugCentral drug card 4914 — structure, indications, targets, approvals, pharmacologic classes (CC BY-SA 4.0)
• ChEMBL CHEMBL3137312 — compound record and bioactivity
• PubChem CID 56640146 — chemical identifiers
• DrugBank DB09183 — drug record
• FDA UNII DE54EQW8T1 — substance identity
• DailyMed: FDA labels for Dasabuvir — current prescribing information (label search)
• UniProt Q96SW2 (CRBN) — target protein
• FDA Adverse Event Reporting System (openFDA FAERS) — adverse-event signals, as aggregated by DrugCentral
• PharmGKB / CPIC — pharmacogenomic label annotations

How this page is built: methodology · editorial policy & corrections.